Objective: To determine the impact of levodopa-carbidopa intestinal gel (LCIG) infusion on different subtypes of freezing of gait (FoG) classified according to levodopa responsiveness in advanced Parkinson disease (PD) patients.
Methods: We retrospectively assessed the presence and severity of FoG in 32 advanced PD patients based on the Unified PD Rating Scale (UPDRS) item 14 score. Different FoG subtypes were inferred from the score variation with oral dopaminergic medications. Modifications following long-term LCIG infusion were analysed. Motor symptoms and motor complications were assessed by UPDRS part III and IV respectively.
Results: FoG related UPDRS score varied from 2.6±0.9 in OFF condition to 0.9±0.8 in the ON condition at baseline and improved to 0.6±0.7 with LCIG infusion (p=0.027). After a mean of 2.59±1.12years of continuous LCIG infusion, Pseudo-ON-FoG improved to a greater extent with LCIG infusion than with oral therapy in 12 patients (38%) and equally well in 8 patients (25%), OFF-type-FoG was controlled equally well in 8 patients (25%) and worsened slightly in 3 patients (9%). Unresponsive-FoG, present in one patient (3%), was unmodified by LCIG infusion.
Conclusions: Even though limited by the subjective simple measure of FoG, this study suggests that patients undergoing LCIG infusion maintain a good long-term control of FoG. Pseudo-on-FoG improves in a considerable percentage of patients and OFF-type-FoG remains well controlled with LCIG infusion. Further studies with a larger number of patients and objective measures of FoG are needed to confirm these findings.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jns.2017.12.012 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Long-term effect and reasons for switching and combining device-aided therapies in Parkinson's Disease.
Neurol Neurochir Pol
January 2025
Department of Neurology, University Medical Centre Ljubljana, Ljubljana, Slovenia.
Introduction: In the advanced stages of Parkinson's disease (PD), when standard drug adjustments fail to sufficiently improve patients' quality of life, device-aided therapies (DATs) such as deep brain stimulation (DBS), continuous subcutaneous apomorphine infusion (CSAI), levodopa-carbidopa intestinal gel infusion (LCIG), levodopa-carbidopa-entacapone intestinal gel infusion, or continuous subcutaneous foslevodoa-foscarbidopa infusion are beneficial in the long run. However, sometimes patients need to switch or combine DATs due to either adverse events or loss of efficacy.
Aim Of Study: The aim of this article was to summarise the existing data on the long-term efficacy and adverse events of DATs, and to review the data on the rationale and efficacy for switching or combining DATs in advanced PD.
Direct Initiation of Levodopa-Carbidopa Intestinal Gel Infusion After a Positive Levodopa Challenge Test in Advanced Parkinson's Disease.
Brain Behav
December 2024
Department of Neurology, Helsinki University Hospital, Helsinki, Finland.
Article Synopsis
- LCIG is a treatment for advanced Parkinson's disease, often starting with a nasojejunal tube (NJT) test phase, but some centers have initiated treatment directly with a PEG-J tube.
- A study compared these two methods in 33 advanced PD patients, evaluating treatment discontinuations, adverse events, and hospital stay length.
- Results showed no significant differences in complications or discontinuations between the two methods, but direct initiation with PEG-J reduced hospital stays significantly.
Effects of levodopa/carbidopa intestinal gel infusion on autonomic symptoms in advanced Parkinson's disease: a systematic review.
Clin Auton Res
December 2024
Department of Neuroscience, Mental Health and Sensory Organs (NESMOS), Sapienza University of Rome, Via di Grottarossa, 1035, 00189, Rome, Italy.
Article Synopsis
- Autonomic failure significantly affects the quality of life for individuals with advanced Parkinson's disease (PD), prompting the need to evaluate the impact of Levodopa/carbidopa intestinal gel (LCIG) on autonomic dysfunction.
- A systematic review identified 16 studies involving 1361 PD patients, assessing the effects of LCIG on gastrointestinal, urinary, and cardiovascular symptoms over time, with most studies reporting improvements or stability.
- While many patients benefited from LCIG, some experienced worsening autonomic symptoms and there were reports of mild adverse events related to the treatment, highlighting the need for further targeted research in this area.
Risk of fall with device-based advanced treatments in Parkinson's disease: a systematic review and network meta-analysis.
J Neurol Neurosurg Psychiatry
November 2024
Edmond J. Safra Program in Parkinson's Disease and Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, UHN, Toronto, Ontario, Canada
Background: Deep brain stimulation (DBS) and infusion therapies are effective treatments for the motor complications of Parkinson's disease (PD), but less established is their role in fall prevention. This systematic review and network meta-analysis (NMA) aimed to evaluate the risk of falls associated with advanced therapies in PD.
Methods: Following PRISMA-NMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses for Network Meta-analyses) guidelines, we searched PubMed, Medline, Embase and CINAHL up to 20 March 2024.
Gender disparity in access to advanced therapies for patients with Parkinson's disease: a retrospective real-word study.
Front Neurol
September 2024
Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.
Background: Gender differences in the access to advanced therapies for Parkinson's disease (PD) are poorly investigated.
Objective: The objective of this study was to investigate the presence of any gender disparity in the access to advanced therapies for PD.
Design: Retrospective study.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!